IP Library Granted Patent US 7,146,210
Granted Patent B2
US 7,146,210 · App. 10/402,327 · Granted Dec 5, 2006

Apparatus and method for optimizing tumor treatment efficiency by electric fields

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,146,210
App. No.
10/402,327
Granted
Dec 5, 2006
Kind
B2
Abstract

The apparatus and method are designed to compute the optimal spatial and temporal characteristics for combating tumor growth within a body on the basis of cytological (as provided by biopsies, etc.) and anatomical data (as provided by CT, MRI, PET, etc.), as well as the electric properties of the different elements. On the basis of this computation, the apparatus applies the fields that have maximal effect on the tumor and minimal effect on all other tissues by adjusting both the field generator output characteristics and by optimal positioning of the insulated electrodes or isolects on the patient's body.

Claims (69)

1. A method for optimizing the selective destruction of dividing cells in a malcontrolled cell growth using a device that subjects the cell growth to an alternating electric field, wherein passage of the electric field through the dividing cells in late anaphase or telophase transforms the electric field into a non-homogeneous electric field that produces an increased density electric field in a region of the dividing cells to induce a structural change in the dividing cell resulting in destruction thereof, the optimization method comprising the steps of:

computing an optimal field map of the positions of electrodes relative to the malcontrolled cell growth in a target area;

arranging the electrodes according to a select pattern relative to the malcontrolled cell growth and computing a vector sum of electric fields to generate an electric field map;

comparing the electric field map to the optimal field map;

changing one of a delivered voltage to the electrodes and a location of the electrodes and computing a vector sum of electric fields to generate an electric field map for the electrodes; and

optimizing a correlation between the generated electric field map and the optimal field map,

wherein the step of optimizing a correlation takes into account an electrode voltage, a wave shape and a position of each electrode, and

wherein the electric field is computed in accordance with the expression:

E

=

V

r

ln

(

R

2

R

1

)

ɛ

coat

ɛ

tissue

where R 1 is the radius of a conductive part of the electrode; R 2 is the electrode radius including a coating disposed on the electrode; and ε coat and ε tissue are the dielectric constants of the electrode coating and tissue, respectively and r is the distance between the electrodes to the point where one wants to calculate the electric field.

2. The method of claim 1 , wherein the step of computing an optimal field map includes the steps of:

(a) inputting characteristics of tissue cells in the target area;

(b) inputting characteristic of the malcontrolled tissue cells in the target area;

(c) inputting anatomical characteristic of the target area;

(d) computing a threshold field intensity in the malcontrolled cell growth;

(e) computing relative sensitivities of surrounding healthy tissue to the electric field;

(f) computing a maximal allowed field intensity at predetermined location; and

(g) computing the optimal field map on the basis of the information generated in step (a) to (f).

3. The method of claim 1 , further comprising the step of:

providing a device that includes:

a first insulated electrode having a first conductor;

a second insulated electrode having a second conductor; and

an electric field source connected to the first and second insulated electrodes for applying the alternating electric field across the first and second conductors to creates a condition in the dividing cells that encourages the destruction thereof.

4. The method of claim 3 , wherein, in the providing step, the first electrode includes a first dielectric member that is in contact with the first conductor, the first dielectric member for placement againts the living tissue to form a capacitor and wherein the second electrode includes a second dielectric member that is contact with the second conductor, the second dielectric member for placement against the living tissue to form a capacitor.

5. The method of claim 1 , wherein the alternating electric field has a frequency of between about 50 KHz to about 500 KHz.

6. The method of claim 1 , wherein the alternating electric field has a frequency of between about 100 KHz to about 300 KHz.

7. The method of claim 3 , wherein, in the providing step, the electric field source generates an alternating voltage waveform at frequencies between about 50 KHz to about 500 KHz.

8. The method of claim 7 , including the step of:

activating the first and second electrodes by the alternating voltage waveform.

9. The method of claim 1 , wherein, in the providing step, the coating of the electrode comprises a potassium tantalate coating.

10. The method of claim 1 , wherein the step of optimizing a correlation comprises the step of:

applying a robust numeric optimization method to optimize the correlation between the generated electric field map and the optimal field map.

11. The method of claim 1 , wherein the select pattern is one of a symmetric pattern and a non-symmetric pattern.

12. The method of claim 1 , wherein the step of computing a vector sum comprises the steps of:

feeding coordinates of all available electrodes; and

computing the vector sum of the fields generated by each electrode at each point in time.

13. The method of claim 1 , wherein the optimization step includes balancing the strength of the electric field at the malcontrolled cell growth and maximizing a difference between electric field strength at the malcontrolled cell growth and the electric field strength at surrounding healthy tissue.

14. The method of claim 1 , wherein the tissue is muscle tissue and ε tissue equals ε muscle .

15. A method to prevent restenosis of arteries after angioplasty, the method comprising the steps of:

providing an apparatus having:

a first insulated electrode;

a second insulated electrode; and

an electric field source for applying an alternating electric field across the first and second conductors;

positioning the first and second insulated electrodes in relation to at least one mass of proliferating cells within at least one artery; and

subjecting the one or more masses of proliferating cells to an alternating electric field, wherein passage of the electric field through the proliferating cells in late anaphase or telophase transforms the electric field into a non-homogeneous electric field that produces an increased density electric field in a region of the cells and induces a structural change in the cells resulting in destruction thereof, wherein subjecting the living tissue to the alternating electric field comprises applying an alternating electric potential having a frequency of between about 50 KHz to about 500 KHz.

16. The method of claim 15 , wherein the step of positioning the first and second insulated electrodes comprises:

placing the first and second electrodes against a chest wall and positioning the electrodes so that the heart and the at least one artery fall within a high density region of the electric field.

17. The method of claim 15 , further including the step of:

placing a stent within the at least one artery, the mass of proliferating cells growing at or near the stent.

18. The method of claim 17 , wherein the stent comprises a conductive stent.

19. The method of claim 15 , wherein, in the subjecting step, the alternating electric potential has a frequency of between about 100 KHz to about 300 KHz.

Assignments (18)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0335 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398 Recorded Aug 19, 2020
From: BPCR LIMITED PARTNERSHIP
To: NOVOCURE GMBH
Reel/Frame 053538/0623 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825 Recorded Apr 14, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052391/0549 →
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052383/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 050110/0098 →
SECURITY INTEREST Recorded May 6, 2019
From: NOVOCURE GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 050395/0398 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045284/0851 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045278/0825 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2018
From: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
To: NOVOCURE LIMITED
Reel/Frame 044858/0416 →
SECURITY INTEREST Recorded Feb 2, 2015
From: NOVOCURE LIMITED
To: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
Reel/Frame 034866/0402 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2013
From: DEUTSCHE BANK TRUST COMPANY AMERICAS
To: NOVOCURE LIMITED
Reel/Frame 031866/0567 →
SECURITY AGREEMENT Recorded Feb 20, 2013
From: NOVOCURE LIMITED
To: DEUTSCHE BANK TRUST COMPANY AMERICAS
Reel/Frame 029845/0135 →
CHANGE OF NAME Recorded May 19, 2011
From: STANDEN LIMITED
To: NOVOCURE LIMITED
Reel/Frame 026311/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2003
From: PALTI, YORAM
To: STANDEN LIMITED
Reel/Frame 014520/0379 →